Dr. Arvin Dar is a tenured Professor in the Departments of Oncological Sciences and Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai, NYC. He is also the Associate Director of the Mount Sinai Center for Therapeutic Discovery and a member of the Tisch Cancer Institute (TCI). Dr. Dar’s research is focused on the integration of genetics and small molecule chemistry to uncover basic principles of signal transduction, with applications in tool development and therapeutics.  Prior to joining Mount Sinai, Dr. Dar was a postdoctoral fellow at UCSF in the laboratory of Kevan Shokat, and before that he completed his PhD at the University of Toronto with Dr. Frank Sicheri. As an Independent PI, Dr. Dar’s laboratory has been researching and developing kinase inhibitors and other small molecule approaches for the treatment of cancer and neurological disorders. This includes new drug development technologies to visualize and modulate higher-order structure and function of cell signaling complexes in vivo. Recently, Dr. Dar co-founded a biotech startup that is developing novel small molecule oncology medicines. In addition, he has received numerous awards and honors, including the NIH Director’s New Innovator Award, Damon-Runyon Rachleff Innovation Award, the Pew Charitable Trusts Pew-Stewart Scholarship for Cancer Research, Pershing Square Sohn Cancer Research Alliance Award, Junior Faculty Award at Mount Sinai, Friedman Brain Institute Scholar Award, and the Mark Foundation for Cancer Research Aspire Award.